EV-075 for Haemorrhagic Fevers (in particular Ebola)

About Haemorrhagic Fevers

Haemorrhagic fevers are a group of illnesses, caused by viruses such as Ebola, Lassa and Marburg that share common clinical symptoms such as high fever and internal and external bleeding. Ebola itself is a very contagious virus that is normally fatal in humans. Ebola has appeared sporadically since it was first recognised in 1976, with its very lethality fortunately restricting its spread under normal conditions.

Current Treatments

We are not aware of any vaccines or treatment options for Ebola haemorrhagic fever. Best care currently involves providing relief of symptoms (supportive care) – the provision of intravenous fluids, oxygen and similar. However, even with best supportive care, death occurs in 50 to 90 percent of infected people.

How EV-075 May Benefit Patients

In pre-clinical studies, the prophylactic treatment of Ebola infections with EV-075 resulted in a survival rate of approximately 60–80% (compared to a 0% survival rate in the untreated arm). In humans, this effect could potentially provide individuals at risk of contracting Ebola with significant protection. It may also provide the basis for effective treatment of individuals who have contracted Ebola.

Current Development Status

EV-075 is in pre-clinical development and GLP studies on an oral formulation are ongoing. EV-075 has shown efficacy in multiple pre-clinical studies, including models of Ebola.